Journal issues > Issue 6, November 2018 > Cytogenetic and molecular testing in lymphoma patients

Cytogenetic and molecular testing in lymphoma patients

By: P. Heimann MD, PhD, H.A. Poirel MD, PhD

SUMMARY

It is now well demonstrated that cytogenetic and molecular testing are valuable tools for the diagnostic, prognostication, and decision of treatment strategy in lymphoproliferative disorders. Here, we will give an overview of the genetic tests that represent current and future clinical assessment tools in the context of lymphoid malignancies. This review has been divided into two distinct but complementary parts. Part I will address the genetic aspects of low grade B-cell lymphomas and will very briefly describe the different technical methods that can be used in routine practice for the clinical management of lymphoid malignancies. Part II will cover aggressive B- and T/NK-cell lymphomas as well as Hodgkin lymphoma and will be published subsequently.

(BELG J HEMATOL 2018;9(6):225–36)

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top